Investors sold shares of Eli Lilly and Co. (NYSE:LLY) on strength during trading on Wednesday. $51.20 million flowed into the stock on the tick-up and $99.21 million flowed out of the stock on the tick-down, for a money net flow of $48.01 million out of the stock. Of all equities tracked, Eli Lilly and had the 0th highest net out-flow for the day. Eli Lilly and traded up $1.31 for the day and closed at $83.40

A number of analysts have commented on the stock. Leerink Swann decreased their price target on shares of Eli Lilly and from $101.00 to $96.00 and set an “outperform” rating for the company in a research note on Monday, May 2nd. Morgan Stanley restated a “hold” rating and set a $88.00 price target on shares of Eli Lilly and in a research note on Saturday, June 4th. BMO Capital Markets restated a “buy” rating and set a $94.00 price target on shares of Eli Lilly and in a research note on Wednesday. Credit Suisse Group AG restated a “buy” rating on shares of Eli Lilly and in a research note on Thursday, May 26th. Finally, Jefferies Group restated a “buy” rating and set a $100.00 price target on shares of Eli Lilly and in a research note on Friday, May 13th. Four equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $95.15.

The firm’s 50 day moving average is $77.53 and its 200 day moving average is $75.85. The company has a market cap of $88.41 billion and a PE ratio of 35.95.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 26th. The company reported $0.86 EPS for the quarter, hitting the consensus estimate of $0.86. The business earned $5.40 billion during the quarter, compared to the consensus estimate of $5.14 billion. During the same quarter in the previous year, the business posted $0.90 earnings per share. Eli Lilly and’s quarterly revenue was up 8.6% compared to the same quarter last year. On average, equities analysts predict that Eli Lilly and Co. will post $3.56 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 9th. Investors of record on Monday, August 15th will be issued a $0.51 dividend. The ex-dividend date is Thursday, August 11th. This represents a $2.04 annualized dividend and a yield of 2.45%.

In related news, major shareholder Lilly Endowment Inc sold 225,000 shares of Eli Lilly and stock in a transaction dated Thursday, July 7th. The stock was sold at an average price of $79.14, for a total value of $17,806,500.00. Following the completion of the sale, the insider now directly owns 126,442,509 shares in the company, valued at approximately $10,006,660,162.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Melissa S. Barnes sold 992 shares of Eli Lilly and stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $73.77, for a total value of $73,179.84. Following the completion of the sale, the senior vice president now owns 10,710 shares of the company’s stock, valued at $790,076.70. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have recently made changes to their positions in LLY. Wells Fargo & Company MN boosted its position in shares of Eli Lilly and by 2.0% in the fourth quarter. Wells Fargo & Company MN now owns 2,102,691 shares of the company’s stock valued at $177,173,000 after buying an additional 41,735 shares during the last quarter. Parsons Capital Management Inc. RI boosted its position in shares of Eli Lilly and by 1.3% in the fourth quarter. Parsons Capital Management Inc. RI now owns 53,289 shares of the company’s stock valued at $4,490,000 after buying an additional 703 shares during the last quarter. Suntrust Banks Inc. boosted its position in shares of Eli Lilly and by 16.8% in the fourth quarter. Suntrust Banks Inc. now owns 255,833 shares of the company’s stock valued at $21,554,000 after buying an additional 36,887 shares during the last quarter. Navellier & Associates Inc boosted its position in shares of Eli Lilly and by 21.6% in the fourth quarter. Navellier & Associates Inc now owns 17,411 shares of the company’s stock valued at $1,467,000 after buying an additional 3,091 shares during the last quarter. Finally, Moors & Cabot Inc. boosted its position in shares of Eli Lilly and by 19.1% in the fourth quarter. Moors & Cabot Inc. now owns 22,421 shares of the company’s stock valued at $1,885,000 after buying an additional 3,594 shares during the last quarter.

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.